Skip to main content

Market Overview

Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study


Immutep (NASDAQ: IMMPannounces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).

  • Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients.
  • The trial, called TACTI-003, will have approximately 160 HNSCC patients. It will evaluate the safety and efficacy of Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck's Keytruda (pembrolizumab), compared to pembrolizumab alone.
  • The first patient will be enrolled in mid-2021.
  • The combination of efti and Keytruda is also being evaluated in Immutep's ongoing Phase 2 TACTI-002 study. 
  • Price Action: IMMP shares were trading 5.84% higher at $2.9 in premarket trading on the last check Tuesday.

Related Articles (MRK + IMMP)

View Comments and Join the Discussion!

Posted-In: neck cancer Phase 2B TrialBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at